Irinotecan
- Generic Name
- Irinotecan
- Brand Names
- Camptosar, Onivyde, Onivyde pegylated liposomal (previously known as Onivyde)
- Drug Type
- Small Molecule
- Chemical Formula
- C33H38N4O6
- CAS Number
- 97682-44-5
- Unique Ingredient Identifier
- 7673326042
- Background
Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cell death. It is a derivative of camptothecin. Irinotecan was approved for the treatment of advanced pancreatic cancer in October, 2015 (irinotecan liposome injection, trade name Onivyde).
- Indication
For the treatment of metastatic colorectal cancer (first-line therapy when administered with 5-fluorouracil and leucovorin). Also used in combination with cisplatin for the treatment of extensive small cell lung cancer. Irinotecan is currently under investigation for the treatment of metastatic or recurrent cervical cancer. Also used in combination with fluorouracil and leucovorin for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy.
- Associated Conditions
- Esophageal Cancer, Ewing's Sarcoma, Gastric Cancer, High Grade Glioma: Glioblastoma (GBM), Metastatic Cervical Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Cancer, Rhabdomyosarcomas, Small Cell Lung Cancer (SCLC), Stage IV Colorectal Cancer, Recurrent, metastatic Colorectal carcinoma, Refractory, metastatic Pancreatic adenocarcinoma
- Associated Therapies
- -
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2020-12-08
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Artios Pharma Ltd
- Target Recruit Count
- 547
- Registration Number
- NCT04657068
- Locations
- 🇺🇸
Cancer Specialists of North Florida, Jacksonville, Florida, United States
🇺🇸Minnesota Oncology Hematology, Maple Grove, Minnesota, United States
🇺🇸University of Alabama at Birmingham, Birmingham, Alabama, United States
Sym021 in Combination With Either Sym022 or Sym023 or Sym023 and Irinotecan in Patients With Recurrent Advanced Selected Solid Tumor Malignancies
- Conditions
- Interventions
- First Posted Date
- 2020-11-24
- Last Posted Date
- 2024-06-26
- Lead Sponsor
- Symphogen A/S
- Target Recruit Count
- 78
- Registration Number
- NCT04641871
- Locations
- 🇺🇸
MD Anderson, Houston, Texas, United States
🇺🇸University of Kansas Medical Center (KUMC), Westwood, Kansas, United States
🇺🇸START Midwest, Grand Rapids, Michigan, United States
FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma
- First Posted Date
- 2020-11-12
- Last Posted Date
- 2024-05-23
- Lead Sponsor
- University of Birmingham
- Target Recruit Count
- 1672
- Registration Number
- NCT04625907
- Locations
- 🇬🇷
University Unit of Pediatric Oncology-hematology - Children's Hospital Agia Sophia, Athens, Greece
🇮🇱Rambam Health Care Campus, Haifa, Israel
🇮🇱Hadassah University Medical Centre, Jerusalem, Israel
A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-10-29
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 816
- Registration Number
- NCT04607421
- Locations
- 🇺🇸
LAC & USC Medical Center, Los Angeles, California, United States
🇺🇸Cedars- Sinai Medical Center, Los Angeles, California, United States
🇺🇸Investigational Drug Service, The Ohio State University Wexner Medical Center, Columbus, Ohio, United States
Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC
- Conditions
- Interventions
- First Posted Date
- 2020-10-14
- Last Posted Date
- 2024-04-30
- Lead Sponsor
- University of Wisconsin, Madison
- Target Recruit Count
- 71
- Registration Number
- NCT04587128
- Locations
- 🇺🇸
University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States
NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-09-07
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 60
- Registration Number
- NCT04539808
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Testing the Addition of an Anticancer Drug, BAY 1895344, to the Usual Chemotherapy With FOLFIRI in Advanced or Metastatic Cancers of the Stomach and Intestines
- Conditions
- Advanced Colorectal CarcinomaMetastatic Digestive System CarcinomaStage IV Colorectal Cancer AJCC v8Advanced Gastric CarcinomaClinical Stage IV Gastric Cancer AJCC v8Advanced Gastroesophageal Junction AdenocarcinomaClinical Stage III Gastric Cancer AJCC v8Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8Metastatic Gastroesophageal Junction AdenocarcinomaStage III Colorectal Cancer AJCC v8
- Interventions
- First Posted Date
- 2020-09-02
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 10
- Registration Number
- NCT04535401
- Locations
- 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸National Cancer Institute Developmental Therapeutics Clinic, Bethesda, Maryland, United States
🇺🇸National Institutes of Health Clinical Center, Bethesda, Maryland, United States
RRx-001 Given With Irinotecan and Temozolomide for Pediatric Patients With Recurrent or Progressive Malignant Solid and Central Nervous System Tumors
- First Posted Date
- 2020-08-24
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- EpicentRx, Inc.
- Target Recruit Count
- 2
- Registration Number
- NCT04525014
- Locations
- 🇺🇸
Texas Children's Cancer Center, Houston, Texas, United States
Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer
- Conditions
- Metastatic Malignant Solid NeoplasmMetastatic Pancreatic AdenocarcinomaUnresectable Malignant Solid NeoplasmUnresectable Neuroendocrine CarcinomaUnresectable Pancreatic AdenocarcinomaStage IV Lung Cancer AJCC v8Metastatic Lung Small Cell CarcinomaMetastatic Neuroendocrine CarcinomaStage III Lung Cancer AJCC v8Stage III Pancreatic Cancer AJCC v8
- Interventions
- First Posted Date
- 2020-08-17
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 96
- Registration Number
- NCT04514497
- Locations
- 🇺🇸
UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States
🇺🇸Smilow Cancer Hospital Care Center-Trumbull, Trumbull, Connecticut, United States
🇺🇸Mayo Clinic in Florida, Jacksonville, Florida, United States
AVELUMAB and CETUXIMAB and mFOLFOXIRI as Initial Therapy for Unresectable Metastatic Colorectal Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2020-08-14
- Last Posted Date
- 2023-09-13
- Lead Sponsor
- Gruppo Oncologico del Nord-Ovest
- Target Recruit Count
- 58
- Registration Number
- NCT04513951
- Locations
- 🇮🇹
U.O. Oncologia Medica 2 Universitaria - Azienda Ospedaliero-Universitaria Pisana Dipartimento di Ricerca Traslazionale e Nuove Tecnologie - University of Pisa, Pisa, Italy
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.